Ekf Diagnostics Share Discussion Threads

[tongosti] 26/11/2021 12:17

Who exactly has profited from a sideways share? No need to reply - it's rhetorical pal. Good luck champ.

[sirshagalot] 26/11/2021 12:09

All i see is some profit taking IMHO.
Fundamentals to me seem intact.

[tongosti] 26/11/2021 11:56

EKF should benefit? Love the broken record argument again. Lol

we are in the midst of a pandemic with no end in sight and yet this stock hasn't gone anywhere in 13 months. ever question yourself why?

Translation - in all likelihood all pandemic related benefits to ekf have all been discounted by late Oct 2020. Been making the same point for over a year now. Did any of you ever read markets are forward looking machines and in the business of continuously discounting the future 12-18 months out?

Seriously folks, get a grip, think critically and grow up if you want to beat the market. more importantly, do away with wishful thinking. Hope is the most expensive word in the world of money - according to Sir John Templeton of course (am sure he knew a thing or two about the proverbial long term)

P.S. MG - care to update us on the latest performance numbers or shall we extrapolate to 2025 so that you're still happy? lol

[sirshagalot] 26/11/2021 11:49

Its the "NU" African virus that has hit the markets on a lot of shares rr,easyjet for example are hit hard for obvious reasons.
Ekf should benefit in a way as i said before covid has legs in it yet!.
Maybe a new vaccine may be needed since existing looses 40% effectiveness against this new variant.

[tongosti] 26/11/2021 11:42

Here we go chaps,73 printing.

Plenty on here have fallen in love with wan’s never changing thesis and refuse to see cold hard facts. Today we are hearing of a new covid related variant and yet ekf still tanks. Doesn’t this merit a proper discussion on this board? This is exactly what you should discuss - are you missing something in your broken record story? Literally.

Made exact same point on Nov 9 2020 but folks were up in arms.

LISTEN to what the market is telling you!

[sirshagalot] 26/11/2021 10:17

opens 3 liter bottle of white lightning

[tongosti] 26/11/2021 10:13

Time to uncork the bubbly then?

[masurenguy] 26/11/2021 09:23

EKF in the BLUE within a big sea of RED this morning !

[tongosti] 25/11/2021 21:15

Fair to say it's toast now?

[tongosti] 24/11/2021 17:26

This breakout is def toast pal. What is less certain (with you being right there) is the (potential) next breakout (if it happens of course - if so I will make sure I climb on board but not feeling super confident we will see something along those lines soon).

[bramble13] 24/11/2021 10:45

Don't be to sure about this break out yet. The day is still early, we have a very crafty mm here.

[tongosti] 24/11/2021 10:14

Another failed breakout attempt. Another message (again) from Mr Market that everything folks talk about here is ALREADY in the price. Only catalyst that may help the share price rocket is a major, major positive surprise. That's what I hope someone tells us here not replay broken records about how markets have yet to catch-up with some anonymous board members here. Good luck chaps - listen to what the market is telling you.

[james188] 23/11/2021 17:06

I also viewed this as positive news. The final part of this particular jigsaw is to appoint the new COO. I also wonder if EKF are going to publish a trading update in the near future. They have been relatively quiet of late, compared to recent years.

[tongosti] 23/11/2021 13:43

CFO is leaving the company just told us. Not sure why but what one can be sure about is Peter Lynch was never a big fan of such high profile departures.

[rivaldo] 23/11/2021 11:01

Indeed wan - an impressive appointment, and noteworthy that the new CFO is described as having "strong sector experience managing both organic and acquisitive growth".

[wan] 23/11/2021 07:30

The evolution of EKF continues with todays news!

Market wisdom has only just begun to acknowledge what the new EKF era might deliver in terms of reliable growth, but perhaps understandably, it's not yet acknowledging the exciting growth that will come from the further execution of their growth strategy. In this regard, I am very confident we can expect more news.

Suffice to say, I thus look forward to EKF climbing up the AIM 100 league table in due course!

[jsredbird] 22/11/2021 17:50

Why the trolls lately tong? I prefer your flashes of genuine market wisdom, which I believe you have.

[tongosti] 22/11/2021 09:25

Morning wan - still waiting for the usual pal. Tic toc

[tongosti] 19/11/2021 12:37

Mg must agree with your assessment. Do you also believe second coming of the lord is also at hand? Lol

[sirshagalot] 19/11/2021 11:43

Due for tick up soon to mid 80,s since stable at current levels.

[rivaldo] 17/11/2021 15:09

News from Medica 2021 (apologies wan if you've already posted this! I don't recall it....)



"EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
By LabMedica International staff writers
Posted on 15 Nov 2021

EKF Diagnostics (Cardiff, Wales, UK) showcased its recently launched STAT-Site WB β-ketone and glucose handheld analyzer at this year’s MEDICA, the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals....

....MEDICA 2021 became the venue for the first public viewing of the new STAT-Site WB β-ketone and glucose handheld analyzer in Europe since its global launch earlier this year. The STAT-Site WB analyzer from EKF is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples. The STAT-Site WB analyzer uses two different strips to provide results in just ten seconds for β-ketones and five seconds for glucose allowing for clear and comprehensive management of diabetes patients displaying early symptoms of ketosis to be quickly treated and then monitored on a regular basis.

EKF also demonstrated its globally successful PrimeStore MTM (Molecular Transport Medium) molecular transport media that gives the user a “snapshot” in time for that sample by preserving and stabilizing DNA and RNA. PrimeStore MTM was designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses, and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications.

In addition to PrimeStore MTM, EKF also demonstrated new product innovations relating to the future control of COVID-19, including the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory without the need for proprietary equipment."

[tongosti] 17/11/2021 14:17

Yes you have been staying that for a very long time. Shame you have tuned out any info received by Mr Market but rather insist on you being 100% certain what the future holds. As the wise man said - uncertainty is uncomfortable but certainty (in this universe) is absurd. Good luck old chap.

[wan] 17/11/2021 07:27

As I stated at the beginning of the above post, EKF are expanding way beyond COVID related testing, which the following exemplifies -

EKF
Welcome to the team, Michael T. Murphy!

With more than 25 years of experience in the Life Sciences industry, Michael’s new role is the Global Business Development Manager for Molecular Diagnostics and Custom Contract Manufacturing Services.

Great things keep coming our way.

Luke Daum
Chief Scientific Officer at EKF Diagnostics

Excited to have Michael onboard at EKF. He brings a wealth of knowledge from his experience at GEHC and beyond. Looking forward to working closely with an experienced Business Development expert to expand our diagnostics products and services at EKF!

EKF
Agreed! Extremely exciting times ahead


Michael has extensive experience and key relationships from operating at the top level, including GE Healthcare/Cytiva and Thermo Fisher. Worth checking out -


Beyond those excellent employees already onboard at EKF, EKF are attracting further high-calibre people, which also says a lot about EKF itself and indeed what the future holds!

[wan] 16/11/2021 15:08

EKF are expanding way beyond covid related testing etc, but nonetheless I believe the following is, at least, a very interesting development.

Yesterday the FDA issued new guidance on Emergency Use Authorization requests on certain types of SARS-CoV-2 tests. As such, the FDA's previous policies did not increase the availability of at-home tests, tests with home specimen collection, or other tests for use outside of a high-complexity CLIA-certified laboratory, including most POC tests, which the FDA is now looking to accommodate, but with a focus on increasing the availability and increased capacity -

FDA, HHS Update COVID-19 Test Emergency Use Authorization Policies
Nov 15, 2021

NEW YORK – The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

In the new document, FDA said it intends to focus its review of Emergency Use Authorization requests on certain types of SARS-CoV-2 tests, including at-home and point-of-care diagnostic tests for use with or without a prescription that can be manufactured in high volumes, i.e., with a manufacturing capacity of at least 500,000 tests per week within three months of receiving EUA.

The agency will also focus on high-volume, lab-based molecular tests — as well as home collection kits for use with these tests — that can expand testing capacity and accessibility, whether through pooling specimens to increase throughput, testing specimens collected at home and shipped to a lab, screening asymptomatic people, or detecting multiple respiratory viruses at once. These tests should also be from experienced developers who have indicated the ability to scale up manufacturing capacity, FDA noted.

Certain lab-based and POC high-volume antibody tests that can measure the amount of antibodies or amount of neutralizing antibodies are also part of the guidance, as well as tests that are supported by a US government stakeholder, such as the Biomedical Advanced Research and Development Authority or the National Institutes of Health's Rapid Acceleration of Diagnostics initiative.

Developers of other kinds of tests not mentioned in the guidance document can pursue market authorization through other pathways, including 510(k) clearance or de novo classification, the agency said.
Full story -

Regarding home specimen collection, PrimeStore MTM effectively already has 510k approval via De Novo certification, and PBS/saline transport media are generally exempt from premarket notification requirements under 510(k) subject to complying with ISO 13485 and FDA Quality System Regulations.

So, EKF's sample collection products are not subject to any of the new restrictions, but developers of new tests would need to satisfy that over 500,000 specimen collection kits can be manufactured and supplied per week. And aside from EKF's industrial partner testing efforts, the acquisition of ADL Health CLIA certified laboratory that's processing thousands of samples on a daily basis, also looks timely given the high-throughput 'fast' testing capability and increasing capacity.

Notes from the FDA document -
"In order for diagnostic tests to significantly increase testing capacity, which has been identified as a US government testing priority, they should be high volume and high throughput and for use on broad patient populations (i.e., not only on symptomatic patients or patients suspected of COVID-19). FDA authorization of high and moderate complexity tests with manufacturing capacities lower than 500,000 tests per week will not sufficiently scale US testing capacity."

"Home specimen collection kits intended for use with high volume and high throughput laboratory-based tests will support and enable increased testing with such tests by increasing their accessibility."

If you scroll down to the bottom of the document to the flow chart, readers will see that for all types of tests, including those utilising home specimen collection kits, that unless high manufacturing capacity is 'in place', the FDA will decline those applications.



To my mind/interpretation, at the very least, this adds to the positive backdrop and underscores EKF as both a current and potential partner of choice on a number of fronts!

Please conduct you own research and make your own interpretations when making investment decisions, as mine could be either wrong or inaccurate.